Compare Crispr Therapeutics AG (CRSP) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs JPMorgan Ultra Short Income ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while JPMorgan Ultra Short Income ETF trades at $50.3 (market cap $42.37B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 8.7× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and JPMorgan Ultra Short Income ETF for 47 Days on average.
| CRSP | JPST | |
|---|---|---|
Market Cap | $4.88B | $42.37B |
Volume | 2,861,747 | 7,889,185 |
Sector | Health | Fixed Income |
52-Week High | $73.97 | $50.78 |
52-Week Low | $44.34 | $50.22 |
Typical Hold Time | 77 Days | 47 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
JPST trades at $50.27 with no price movement in the last 24 hours. The ETF shows bearish technical signals with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights institutional position adjustments and the fund's role in retirement strategies. Dividend distributions of $0.17 per share are scheduled through October 2026.
The ultra-short income ETF faces headwinds from rising rate expectations but benefits from demand for cash alternatives. Performance lags behind peers with higher expenses, though institutional interest persists. Key risks include interest rate sensitivity and competitive pressure from similar funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
